Trial Profile
A retrospective study to evalauate percentage of prostate specific antigen decline in metastatic castration resistant prostate cancer patients treated with Abiraterone and Enzalutamide
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Mar 2017
Price :
$35
*
At a glance
- Drugs Abiraterone (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 25 Mar 2017 New trial record
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium